SNET NEWS!
Tuesday, February 26 2019 4:00 PM, EST SourcingLink.net Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboration of NanoSmart's Proprietary Targeted Drug Delivery System for Cancer Drugs GlobeNewswire "Press Releases"
San Francisco, CA , Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SourcingLink.net (OTC PINK: SNET), an early stage oncology company, is a pioneering company based in San Francisco, California , USA. The company announced today that it signed a Letter of Intent to collaborate with NanoSmart Pharmaceuticals, Inc. , a California -based company developing novel drug formulations to treat cancer. The collaboration includes co-development and an exclusive, world-wide license for specific formulations to treat cancer utilizing NanoSmart's proprietary targeted drug delivery system that is designed to enhance delivery of drugs to a wide variety of cancer tumors.
SourcingLink.net is excited about the collaboration opportunity because new or already-approved chemotherapy drugs can be reformulated with greater efficacy and safety for treating cancer patients. The company believes that the reformulated drugs, subject to approval by the FDA and/or regional regulatory bodies, may be used as a monotherapy, or as a combo-therapy with SNETs autologous cellular immuno-therapy approach, or with other therapies such as immune check point inhibitors. SNET expects to enter into a full exclusive world-wide licensing and co-development agreement with NanoSmart under the terms of the Letter of Intent signed on February 25th, 2019 .
The use of NanoSmart's enhanced drug delivery platform combined with pharmacogenomics and liquid biopsy for personalizing the therapy should augment cancer drug effectiveness and safety, and improve treatment monitoring, according to the company. Currently, SNET is focused on developing its core autologous extracorporeal immuno-therapy device for a durable response.
About SourcingLink.net : SourcingLink.net, Inc. ("SNET") is a pioneering oncology company dedicated to developing , manufacturing and commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. SourcingLink.netpridesitself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies incancer research, biotechnology and healthcare. SourcingLink.netis currently engaging in research and development of therapeutics for oncology. SourcingLink.netis committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.
Forward-looking Statements:
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as expect, believe or plan, by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.
One Sansome Street , Suite 3500 San Francisco, CA 94104 Phone: 415-869-1038 Fax: 415-946-8801 email: info@sourcinglink.net website:www.sourcinglink.net
Source: SourcingLink.net, Inc.
